These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

9273 related items for PubMed ID: 1622150

  • 1. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH, Ganapathi R.
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Oct; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 5. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
    Ganapathi R, Grabowski D, Schmidt H, Bell D, Melia M.
    Cancer Res; 1987 Jul 01; 47(13):3464-8. PubMed ID: 2884031
    [Abstract] [Full Text] [Related]

  • 6. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE.
    Cancer Res; 1990 Sep 15; 50(18):5931-6. PubMed ID: 1975512
    [Abstract] [Full Text] [Related]

  • 7. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.
    Takashima K, Fujiwara H, Inada S, Atsuji K, Araki Y, Kubota T, Yamagishi H.
    Anticancer Res; 2006 Sep 15; 26(5A):3327-32. PubMed ID: 17094448
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 9. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y.
    Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778
    [Abstract] [Full Text] [Related]

  • 10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 11. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [Abstract] [Full Text] [Related]

  • 12. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
    Berezhnaya NM, Vinnichuk YD, Belova OB.
    Exp Oncol; 2008 Mar 15; 30(1):52-5. PubMed ID: 18438341
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
    Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G.
    Cancer Res; 1988 May 01; 48(9):2372-6. PubMed ID: 3258541
    [Abstract] [Full Text] [Related]

  • 14. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E, Lafreniere R, Mulé JJ, Schwarz SL, Rosenberg SA.
    Cancer Res; 1986 Nov 01; 46(11):5633-40. PubMed ID: 3489526
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
    Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D.
    Cancer Res; 1990 Nov 01; 50(21):6793-9. PubMed ID: 1698543
    [Abstract] [Full Text] [Related]

  • 16. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M, Salvi C, Bassi C, Sensi M, Parmiani G.
    Ann Ist Super Sanita; 1990 Nov 01; 26(3-4):423-32. PubMed ID: 2091504
    [Abstract] [Full Text] [Related]

  • 17. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
    Gorelik E, Gunji Y, Herberman RB.
    J Immunol; 1988 Mar 15; 140(6):2096-102. PubMed ID: 3126240
    [Abstract] [Full Text] [Related]

  • 18. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K, Yasumoto K, Yano T, Matsuzaki G, Sugimachi K, Nomoto K.
    Cancer Res; 1991 Oct 01; 51(19):5261-5. PubMed ID: 1833049
    [Abstract] [Full Text] [Related]

  • 19. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
    Saijo N, Ozaki A, Sakurai M, Ishihara J, Takahashi H, Sasaki Y, Hoshi A, Hamburger AW.
    Jpn J Cancer Res; 1986 May 01; 77(5):487-93. PubMed ID: 3089980
    [Abstract] [Full Text] [Related]

  • 20. Abnormally banded chromosomal regions in doxorubicin-resistant B16-BL6 murine melanoma cells.
    Slovak ML, Hoeltge GA, Ganapathi R.
    Cancer Res; 1986 Aug 01; 46(8):4171-7. PubMed ID: 3731084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 464.